Business
AlzeCure Carries out a Rights Issue of Approximately SEK 48.5 million
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE RUSSIAN FEDERATION, BELARUS, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ...
About this update from Alzecure Pharma Ab
[{"type":"text","content":"NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE RUSSIAN FEDERATION, BELARUS, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE CONTRAVENING TO ANY APPLICABLE RULES. ADDITIONAL RESTRICTIONS ARE APPLICABLE, PLEASE SEE "IMPORTANT INFORMATION" IN THE END OF THIS PRESS RELEASE.","length":486,"tagName":"p"},{"type":"text","content":"STOCKHOLM, SE / ACCESS Newswire / June 16, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB ("AlzeCure" or the "Company"), a pharmaceutical company that develops a broad portfolio of small molecule drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announces that the Board of Directors has resolved on a new share issue of approximately SEK 48.5[1] million with preferential rights for existing shareholders (the "Rights Issue"). The Rights Issue is subject to approval by an extraordinary general meeting to be held on 2 July 2025. The record date for participation in the Rights Issue is 4 July 2025. According to the terms of the Rights Issue, one (1) existing share in AlzeCure entitles the holder to one (1) subscription right, and four (4) subscription rights entitle the holder to subscribe for one (1) new share at a subscription price of SEK 2.20 per share. The Rights Issue is secured to approximately 42 percent through subscription undertakings from existing shareholders, including members of the Company's management and Board of Directors. In order to enable additional capital raise, the Board may also resolve on the exercise of an over-allotment option of up to approximately SEK 10 million (the "Over-Allotment Option"). If the Over-Allotment Option is exercised in full, the total gross proceeds may amount to approximately SEK 58.5 million. A separate notice to the extraordinary general meeting will be published.","length":1575,"tagName":"p"},{"type":"text","content":""We are very pleased that all of our major existing shareholders, as well as all members of the Board of Directors, support our exciting projects by committing to subscribe for their respecti...